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Abstract 
Background: MP‑AzeFlu, intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP), is 
superior to AZE or FP alone for treatment of allergic rhinitis (AR). However, the precise anti‑inflammatory mechanism 
of action of MP‑AzeFlu has not been characterized.
Objective: To investigate the anti‑inflammatory effects of MP‑AzeFlu compared with AZE or FP alone in an 
established in vitro model of eosinophilic inflammation.
Methods: Nasal mucosal epithelial cells and peripheral blood eosinophils were obtained from human volunteers. 
Epithelial cells were stimulated with 10% fetal bovine serum (FBS) in the presence of MP‑AzeFlu, AZE, or FP (1:102 
to 1:105 dilution). Concentrations of interleukin (IL)‑6, IL‑8, and granulocyte–macrophage colony‑stimulating factor 
(GM‑CSF) were measured by ELISA. Eosinophils were incubated in 10% human epithelial cell–conditioned medium 
(HECM) and survival assessed by trypan blue dye exclusion. Results are expressed as mean ± SEM percentage 
secretion/survival compared with FBS/HECM (respectively).
Results: FP and MP‑AzeFlu (all dilutions) and AZE (1:102) significantly reduced IL‑6 secretion and eosinophil survival 
compared with positive controls. At 1:102 dilution, IL‑6 secretion was significantly lower with MP‑AzeFlu (38.3 ± 4.2%, 
compared with FBS = 100%) than with AZE (76.1 ± 4.9%) or FP (53.0 ± 4.9%). At 1:102 dilution, eosinophil survival was 
significantly lower with MP‑AzeFlu at day 3 (17.5 ± 3.0%) and day 4 (2.4 ± 1.4%, compared with HECM = 100%) than 
with AZE (day 3: 75.2 ± 7.2%; day 4: 44.0 ± 9.7%) or FP (day 3: 38.5 ± 3.5%; day 4: 14.6 ± 4.0%).
Conclusion: Greater reductions in cytokine secretion and eosinophil survival observed with MP‑AzeFlu in vitro may 
underlie MP‑AzeFlu’s superior clinical efficacy vs. AZE or FP alone observed in AR patients.
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propionate, Allergic rhinitis, In vitro model
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Background
Allergic rhinitis (AR) is one of the most common 
chronic diseases, impairing quality of life and causing 
billions of dollars of lost productivity annually [1]. 
AR is characterized by upper airway inflammation, 
sneezing, and nasal congestion, drainage, and itching 
[1]. Inflammatory mediators and cells in AR include 
elevated levels of proinflammatory cytokines and 
eosinophil infiltration [2–5].
Current guidelines recommend intranasal 
corticosteroids for treatment of AR and, in some 
cases, the use of oral or intranasal antihistamines [1, 
6, 7]. Unfortunately, many patients do not achieve 
full control of their symptoms and are not satisfied 
with their treatment [8]. Combination therapy may 
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be considered for patients with inadequate response 
to monotherapy [1] or when a prompt response to 
initial therapy is desired [6]. In particular, combined 
intranasal azelastine hydrochloride (AZE) and 
intranasal fluticasone propionate (FP) in a single 
intranasal formulation (MP-AzeFlu) is recommended 
as more effective than monotherapy [8] and as a first-
line option for moderate-to-severe AR [7, 8].
In randomized studies, MP-AzeFlu was more effective 
among patients with seasonal AR and perennial AR 
than AZE or FP alone, [9–13] and was more effective 
among patients with non-AR than FP alone [14]. In 
addition, studies in real-world settings in Europe 
found significant improvements in AR symptoms with 
MP-AzeFlu therapy, [15, 16] and a 1-year study of 
MP-AzeFlu vs. FP alone provided support for the long-
term efficacy and safety of MP-AzeFlu in persistent 
rhinitis [17]. A retrospective US claim database study 
of AR patients with comorbid asthma has shown, that 
the AR and asthma related therapy costs were lower 
when the patients have been treated with MP-AzeFlu 
than with a free combination of intranasal steroid and 
intranasal antihistamine [18].
Mechanistic studies have examined the effect of 
FP (alone and in combination with the antihistamine 
loratadine) on the expression of inflammatory mediators, 
including proinflammatory cytokines and eosinophils 
[19–24]. Typically, FP downregulated cytokine 
expression and reduced eosinophil survival in these 
studies, although findings are mixed. In addition, AZE—
alone or in combination with other agents—was found 
to suppress inflammatory markers in several in  vitro 
studies [25–27]. However, the mechanism of action of 
combined AZE and FP, specifically MP-AzeFlu’s effects 
on inflammatory mediators, has not been characterized. 
In particular, it is unknown whether there may be an 
enhanced anti-inflammatory effect of the two drugs in 
combination, compared with the individual components, 
which might underlie the superior clinical efficacy [9–14] 
of the combination compared with monotherapy.
To study the role of inflammatory mediators in upper 
airway diseases and the mechanism of action of anti-
inflammatory drugs in these diseases, an in vitro model 
was developed utilizing cultured primary isolated nasal 
mucosal epithelial cell cultures and peripheral blood 
eosinophils [28–31]. This in  vitro model has been used 
previously to compare the anti-inflammatory effects of a 
number of drugs including corticosteroids, chromones, 
anti-leukotrienes, and second generation antihistamines, 
[24, 28–34] demonstrating that it is a good model to 
study the mechanisms of action of these classes of 
drugs. In a previous study using this in vitro model, the 
combination of the corticosteroid mometasone furoate 
and the antihistamine desloratadine reduced interleukin 
(IL)-6 and (sICAM)-1 secretion and inhibited eosinophil 
survival induced by epithelial secretions compared with 
either agent alone [29].
The objective of the current study was to investigate 
the anti-inflammatory effects of MP-AzeFlu compared 




AZE and FP were provided by MEDA Pharma (Bad 
Homburg, Germany). Other materials were purchased 
from commercial sources (see Additional file 1).
Study population
Nasal mucosa specimens were obtained from 12 patients 
(nine men, three women), ranging in age from 34 to 
73  years (mean ± standard deviation, 58.2 ± 3.5  years), 
who underwent nasal corrective surgery for septal 
dysmorphy, turbinate hypertrophy, or both. The diagnosis 
of septal dysmorphy and turbinate hypertrophy was based 
on the clinical history and nasal endoscopic exploration. 
Skin-prick test was positive (allergen sensitization) in 
three patients (25.0%). None of the patients in this study 
had clinical AR, chronic rhinosinusitis (CRS), nasal 
polyps (NP), and/or asthma. Patients were excluded 
from this study if they were receiving topical or systemic 
glucocorticoids or antihistamine treatment 4 weeks prior 
to the surgery or had an upper or lower airway infection 
2  weeks prior to the surgery. All patients gave informed 
consent to participate in the study at the time of surgery. 
Tissues used in this study were obtained from the Biobank 
BTIRCE—R100311-016 at Institut d’Investigacions 
Biomèdiques August Pi i Sunyer (IDIBAPS). Scientific and 
Ethics Committee of Hospital Clínic de Barcelona gave 
the ethical clearance for this process.
Normodense eosinophils were obtained from nine 
volunteers (seven women, two men), ranging in age 
from 39 to 74  years (mean ± standard deviation, 
59.1 ± 13.6  years) with > 3% peripheral blood eosinophils 
(mean ± standard deviation, 7.7 ± 1.4%). Patients 
were excluded if they received topical or systemic 
glucocorticoid or antihistamine treatment 4  weeks prior 
to blood extraction or if they had an upper or lower airway 
infection two weeks prior to blood extraction. Skin-prick 
test was positive (allergen sensitization) in four patients 
(44%). Two of the patients had AR (22%), four patients 
had CRS with NP (44%), and three patients had CRS with 
NP and asthma (33%). All patients gave informed consent 
to participate in the study prior to the venipuncture. 
Scientific and Ethics Committee of Hospital Clínic de 
Barcelona gave the ethical clearance for this process.
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Epithelial cell isolation, characterization, and culture
Nasal mucosa specimens were placed in Ham’s F-12 
medium supplemented with 100  UI/mL penicillin, 
100  µg/mL streptomycin, and 2  µg/mL amphotericin 
B (Ham’s PS) and immediately transported to the 
laboratory. Epithelial cells from nasal mucosa were 
isolated by protease digestion using a technique reported 
previously [23, 24, 28–35] and described briefly in 
Additional file  1. Culture of epithelial cells is also 
described in Additional file 1.
Dilution of MP‑AzeFlu
Both azelastine hydrochloride and fluticasone propionate 
were diluted with dimethyl sulfoxide (DMSO) up 
to 2.39 × 10−2  M and 7.29 × 10−3  M, respectively. 
These dilutions from each drug (tenfold concentrated 
compared with MP-AzeFlu) were diluted with culture 
medium to 2.39 × 10−3 M (azelastine) and 7.29 × 10−4 M 
(fluticasone), i.e., the concentration of azelastine 
hydrochloride and fluticasone propionate present in 
MP-AzeFlu. Further dilutions (from dilution 1:102 to 
1:105) were prepared with culture medium.
Generation of human epithelial cell–conditioned media
When epithelial cell cultures reached 80% confluence, 
the hormonally defined serum-free media were switched 
to RPMI-1640 media supplemented with antibiotics 
(penicillin 100  UI/mL and streptomycin 100  μg/mL), 
amphotericin B (2  μg/mL), glutamine (150  μg/mL), and 
HEPES buffer (25  nM). Because previous studies have 
shown that non-stimulated epithelial cells produce low 
levels of cytokines, [23, 24, 28–35] human epithelial cell–
conditioned media (HECM) was generated by incubating 
cells with fetal bovine serum (FBS) at 10% for 24 h. The 
culture supernatant (HECM) was harvested from wells, 
centrifuged at 400  g (10  min, 25  °C), sterilized through 
0.22 µm filters, and stored at − 80 °C. In order to reduce 
the variability, the conditioned media of nasal mucosa 
(N = 12) was mixed before being used in eosinophil 
experimental protocols.
To study the effect of MP-AzeFlu on cytokine 
production, Ham’s HD was switched to RPMI (1 mL) in 
the presence or absence of MP-AzeFlu (dilution 1:102 
to 1:105, as described in Additional file 1) or equivalent 
dilutions of AZE (from 2.39 × 10−5  M to  10−8  M) or 
FP (from 7.29 × 10−6  M to  10−9  M) for 1  h before the 
addition of 10% FBS. After 24  h, the supernatant was 
harvested from cultures, centrifuged at 400 g for 10 min 
at room temperature, sterilized through 0.22  µm filters, 
and stored at -80  °C until used. Because both AZE and 
FP were diluted in dimethyl sulfoxide (DMSO) when 
preparing the MP-AzeFlu formulation, we investigated 
the effect of DMSO at the highest final concentration 
present in the culture medium on epithelial cell viability 
and cytokine secretion.
Epithelial cell viability
Cell viability after treatment was analyzed by incubation 
of cells with the tetrazolium salt XTT (Cell Proliferation 
Kit II) for 3 h, following the manufacturer’s instructions. 
Absorbance was measured in duplicate at 490 nM.
Enzyme‑linked immunoassays of cytokines and sICAM‑1
Concentrations of granulocyte–macrophage colony-
stimulating factor (GM-CSF), IL-6, IL-8, and sICAM-1 
were measured in HECM using commercial enzyme-
linked immunosorbent assay (ELISA) kits. Cytokines 
selected for analysis were those found at detectable 
levels in previous studies in which this model was used. 
The assay detection ranges were 15.6–1000  pg/mL for 
GM-CSF, 9.38–600  pg/mL for IL-6, and 31.2–2000  pg/
mL for both IL-8 and sICAM-1. To verify that the 
substances used in the different experiments (AZE, FBS, 
FP) did not affect the ELISA results, wells containing 
either culture media alone or media with the highest 
drug concentration used in the different protocols were 
compared (N = 3). None of the substances showed any 
intrinsic effect on the ELISA final values. In order to 
avoid variability in cytokine concentration caused by 
differences in the number of cells present in each culture 
well, cytokine production was normalized by optical 
density value obtained by the cell proliferation assay.
Isolation of peripheral blood eosinophils
Isolation of eosinophils from peripheral blood samples is 
described in Additional file 1.
Assessment of eosinophil survival
Eosinophils (2.5 × 105  cells/well) were incubated on 
24-well tissue culture plates with RPMI (2  mL) in the 
presence or absence of MP-AzeFlu (dilution 1:102 to 
1:105) or equivalent dilutions of AZE (from 2.39 × 10−5 M 
to  10−8M) or FP (from 7.29 × 10−6M to  10−9M) for 1  h 
before the addition of epithelial cell secretions at 10%. 
Eosinophil survival index was assessed at 24  h (day 1), 
48 h (day 2), 72 h (day 3), and 96 h (day 4) of incubation 
by trypan blue dye exclusion. Because dead eosinophils 
become lysed and, consequently, the number of cells 
present in the culture wells decreases, the results were 
calculated using the eosinophil survival index instead of 
the percentage of surviving cells. The eosinophil survival 
index was calculated as follows: number of eosinophils 
recovered multiplied by percentage of eosinophil viability 
divided by number of eosinophils delivered on day 0. 
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To reduce the variability caused by the incubation of 
eosinophils with HECM obtained from different nasal 
mucosa, a mixture of HECM was created with the 
cell supernatants from all nasal mucosal epithelial cell 
cultures, and this HECM was used in all eosinophil 
experimental protocols. Because FP was diluted in 
DMSO and the HECM added to the eosinophil cultures 
contained 10% FBS, we investigated the effect of DMSO 
and FBS on eosinophil survival. Neither DMSO nor FBS 
at the higher final concentration had a significant effect 
on eosinophil survival (data not shown).
Statistical analysis
Statistical procedures were performed using SPSS 16.0 
software (IBM, Armonk, NY, USA). Results are expressed 
as mean ± standard error of the mean normalized by the 
optical density value obtained by the cell proliferation 
assay. A non-parametric test, the Wilcoxon signed rank 
test, was used in cytokine secretion experiments, and 
analysis of variance (ANOVA) with the Dunnett multiple 
comparisons test was used for statistical comparisons in 
eosinophil survival experiments. P < 0.05 was considered 
statistically significant.
Results
Effect of FBS on cytokine and sICAM‑1 secretion
In nasal mucosal epithelial cell cultures, FBS increased 
the secretion of IL-6, IL-8, GM-CSF, and sICAM-1 
compared with control medium (Table 1).
Dose response of MP‑AzeFlu, AZE, and FP on cytokine 
and sICAM‑1 secretion induced by FBS in nasal mucosal 
epithelial cells
AZE at 1:102 dilution significantly inhibited FBS-induced 
IL-6 release and increased FBS-induced GM-CSF secretion 
from nasal mucosal epithelial cells compared with FBS 
alone (Table  2). FP showed a dose-dependent inhibitory 
effect on FBS-induced secretion of IL-6, IL-8, and GM-CSF 
at 1:102 to 1:105 dilutions. MP-AzeFlu, at dilutions 1:102 to 
1:105, showed a dose-dependent inhibitory effect on FBS-
induced secretion of IL-6 and IL-8. GM-CSF secretion 
was inhibited by MP-AzeFlu from 1:103 to 1:105 dilutions, 
with no effect at 1:102 dilution. AZE, FP, and MP-AzeFlu 
showed no effect on FBS-induced sICAM-1 secretion.
Comparison of MP‑AzeFlu, AZE, and FP effects 
on FBS‑induced cytokine secretion at the same drug 
dilutions
When comparing the effect of FP with MP-AzeFlu 
(from dilutions 1:102 to 1:105), there were no significant 
differences on the inhibition of GM-CSF or IL-8 secretion. 
However, with each drug at dilution 1:102, the inhibitory 
effect of MP-AzeFlu on IL-6 secretion was significantly 
greater than that of AZE or FP, as shown by the lower levels 
of IL-6 secretion with MP-AzeFlu (Fig.  1; see Table  2 for 
underlying findings at dilution 1:102). In addition, the effect 
of FP was significantly greater than the effect of AZE. At 
higher dilutions (1:103 to 1:105) of FP and MP-AzeFlu, 
there were no significant differences between drugs in the 
inhibition of IL-6 secretion.
Time course of MP‑AzeFlu (dilution 1:102) effects 
on HECM‑induced eosinophil survival from days 1 to 4
HECM at 10% from nasal mucosal epithelial cells 
significantly increased eosinophil survival when compared 
with control medium from days 1 to 4 (Fig. 2). MP-AzeFlu 
at 1:102 dilution showed a time-dependent inhibitory effect 
on HECM-induced eosinophil survival from days 2 to 4.
Dose response and time course of MP‑AzeFlu, AZE, and FP 
on HECM‑induced eosinophil survival at days 3 and 4
At days 3 and 4, MP-AzeFlu and FP (dilution 1:102 to 
1:105) significantly inhibited HECM-induced eosinophil 
survival (Table  3). However, AZE showed an inhibitory 
effect only at dilution 1:102. At days 3 and 4, the inhibitory 
effect of MP-AzeFlu at dilution 1:102 was significantly 
greater than either AZE or FP at the same dilution, as 
shown by the lower levels of eosinophil survival with 
MP-AzeFlu (Fig.  3, see Table  3 for underlying findings 
at dilution 1:102). In addition, the effect of FP at dilution 
1:102 was significantly greater than the effect of AZE 
at the same dilution. No differences were found when 
comparing the inhibitory effect of FP with that of 
MP-AzeFlu from dilutions 1:103 to 1:105.
Discussion
This report shows clear mechanistic effects that are 
consistent with and may underlie the superior clinical 
efficacy of MP-AzeFlu compared with corticosteroid or 
antihistamine alone.
Table 1 Effect of FBS on cytokine secretion from epithelial 
cells
Results are expressed as mean ± SEM. The Wilcoxon signed‑rank test was used 
for analysis
FBS fetal bovine serum, GM‑CSF granulocyte–macrophage colony‑stimulating 
factor, IL interleukin, SEM standard error of the mean, sICAM‑1 soluble 
intercellular adhesion molecule‑1
pg/mL normalized by tetrazolium XTT P N
Control 10% FBS
IL‑6 679.9 ± 189.2 2448.0 ± 539.7 < 0.001 9
IL‑8 4119.0 ± 987.3 12,685.0 ± 1624.0 < 0.001 9
GM‑CSF 163.1 ± 40.7 820.2 ± 257.8 < 0.001 9
sICAM‑1 287.7 ± 63.4 439.6 ± 101.6 < 0.05 9
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Key findings of this study include: (1) FP and 
MP-AzeFlu at all tested dilutions, and AZE at 1:102 
dilution, significantly reduced secretion of IL-6 compared 
with FBS-induced secretion; (2) at 1:102 dilution of each 
agent, the reduction of IL-6 secretion by MP-AzeFlu 
was significantly greater than with AZE or FP alone; (3) 
FP and MP-AzeFlu, at all tested dilutions, and AZE at 
dilution 1:102, significantly reduced eosinophil survival at 
days 3 and 4 compared with HECM alone; and (4) at 1:102 
dilution of each agent, the decrease of eosinophil survival 
induced by MP-AzeFlu at days 3 and 4 was significantly 
greater than with AZE or FP alone.
Findings of the current study are largely consistent 
with previous research with this in  vitro model, further 
validating the model. As in earlier studies, we found that 
secretion of IL-6, IL-8, GM-CSF, and sICAM-1 from 
nasal mucosa epithelial cells was increased in response to 
FBS, [23, 24, 28–31, 35] and HECM increased eosinophil 
survival [24, 28–31].
In the present study, the corticosteroid FP and the 
formulation MP-AzeFlu reduced IL-6 and GM-CSF 
secretions from nasal mucosa epithelial cells relative 
to FBS. This is consistent with previous findings for the 
intranasal corticosteroids budesonide, beclomethasone 
dipropionate, mometasone furoate, FP, and fluticasone 
furoate [23, 24, 29, 30, 35]. In this study, MP-AzeFlu 
findings for IL-8, GM-CSF, and sICAM-1 differed little 
from FP alone. We also found that FP and MP-AzeFlu 
reduced eosinophil survival relative to HECM, consistent 
with previous findings for intranasal corticosteroids [24, 
29, 30].
In the present study, the antihistamine AZE reduced 
IL-6 and GM-CSF secretion and eosinophil survival only 
at 1:102 dilution. These reductions are consistent with 
previous findings for the antihistamine desloratadine [29, 
31]. Our findings for AZE are also consistent with those 
of previous in  vitro studies that found AZE decreased 
inflammatory markers [25–27]. A possible mechanism 
for these effects has been suggested by research showing 
that AZE exhibits direct activity on transient receptor 
potential vanilloid 1 ion channels in mouse neuronal 
cells [36]. We found that AZE did not significantly reduce 
ICAM-1 expression, in contrast to an earlier study that 
found such a reduction [37].
The stronger effects of MP-AzeFlu on IL-6 secretion 
and eosinophil survival in the current study, compared 
with either AZE or FP alone, mirror and possibly 
underlie the stronger clinical efficacy of the MP-AzeFlu 
combination compared with its components [9–14]. The 
relative magnitude of in  vitro effects for MP-AzeFlu vs. 
AZE or FP alone (Figs. 1, 3) appear similar to the relative 
magnitude of clinical effects of these agents in treatment 
of AR. For example, the reduction in total nasal symptom 
Table 2 Effect of  AZE, FP, and  MP-AzeFlu on  cytokine 
and sICAM-1 secretion from nasal mucosal epithelial cells
Results are expressed as mean ± SEM. The Wilcoxon signed‑rank test was used 
for analysis. *P < 0.05 compared with 10% FBS–induced secretion
AZE azelastine hydrochloride, FBS fetal bovine serum, FP fluticasone propionate, 
GM‑CSF granulocyte‑macrophage colony‑stimulating factor, IL interleukin, MP‑
AzeFlu intranasal AZE and intranasal FP in a single device, SEM standard error of 
the mean, sICAM‑1 soluble intercellular adhesion molecule‑1
Agent/dilution Secretion, compared with FBS (%) N
IL‑6 IL‑8 GM‑CSF sICAM‑1
Control media 15.3 ± 2.1* 18.0 ± 2.7* 44.3 ± 4.7* 65.9 ± 5.1* 9
10% FBS 100 100 100 100 9
AZE
 1:102 76.1 ± 4.9* 90.1 ± 5.8 223.5 ± 34.9* 95.2 ± 2.3 9
 1:103 88.7 ± 4.3 87.0 ± 5.9 93.8 ± 6.0 92.8 ± 4.6 9
 1:104 84.6 ± 8.3 93.3 ± 3.3 89.7 ± 5.8 96.9 ± 1.8 9
 1:105 90.1 ± 3.8 91.0 ± 5.3 87.6 ± 3.8 98.9 ± 1.1 9
FP
 1:102 53.0 ± 4.9* 58.5 ± 2.3* 58.2 ± 5.9* 85.2 ± 3.5 9
 1:103 59.1 ± 5.4* 62.0 ± 5.7* 60.2 ± 5.8* 81.8 ± 5.4 9
 1:104 57.7 ± 6.6* 60.4 ± 3.6* 56.2 ± 6.5* 87.0 ± 3.4 9
 1:105 75.3 ± 6.9* 65.4 ± 5.9* 65.0 ± 7.2* 84.9 ± 7.3 9
MP‑AzeFlu
 1:102 38.3 ± 4.2* 55.3 ± 3.4* 126.9 ± 9.8 84.0 ± 4.8 9
 1:103 55.0 ± 6.5* 60.8 ± 4.6* 61.7 ± 5.7* 86.3 ± 6.0 9
 1:104 52.9 ± 3.1* 60.8 ± 3.2* 57.9 ± 5.3* 92.7 ± 3.2 9




















































Fig. 1 Comparison of AZE, FP, and MP‑AzeFlu effects on FBS‑induced 
secretion of IL‑6 from nasal mucosal epithelial cells. Epithelial cells 
were incubated for 24 h with culture medium (white column), 10% 
FBS (black), or 10% FBS plus AZE (diagonally striped), FP (horizontally 
striped), or MP‑AzeFlu (grey) at dilution 1:102. Results are expressed 
as mean ± SEM percentage of IL‑6 secretion compared with FBS. 
The Wilcoxon signed‑rank test was used for analysis (N = 9). *P < 0.05 
compared with 10% FBS. AZE azelastine hydrochloride, FBS fetal 
bovine serum, FP fluticasone propionate, IL interleukin, MP‑AzeFlu 
intranasal AZE and intranasal FP in a single device. SEM standard error 
of the mean
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score in 2-week clinical trials was 3.3–4.5 points with 
AZE and 3.8–5.1 points with FP, compared with a 
reduction of 5.3–5.6 points with MP-AzeFlu [38].
There is good reason to believe our in  vitro findings 
may elucidate the mechanism of action of MP-AzeFlu 
in AR. The inflammatory mediators IL-6, GM-CSF, and 
IL-8, as well as eosinophils, play important roles in airway 
inflammatory diseases. IL-6 is a proinflammatory cytokine 
with pleiotropic expressions consistent with a primary 
role in the pathogenesis of local inflammation [39]. IL-6 
mediates many biologic functions, acting as an endogenous 
pyrogen, stimulating the acute phase response, stimulating 
T lymphocytes, inducing terminal differentiation of 
B lymphocytes, and stimulating immunoglobulin 
production [39]. It is well known that CRS is associated 
with elevated levels of IL-6, as upregulation has been 
reported in peripheral blood mononuclear cells (PBMCs), 
[40] on sinus mucosa biopsies, [41–43] and in nasal 
secretions [44] from patients suffering from CRS. In fact, 
increased expression of IL-6 messenger RNA in nasal 
mucosa biopsies of patients suffering from persistent AR 
has been reported [45], pollen exposure to patients with 
AR significantly increased IL-6 in nasal secretions [5], 
and nasal secretions were increased in allergic patients 
after intranasal administration of IL-6 [39]. In addition, it 
has been reported that primary cultures of human nasal 
epithelial cells from patients with AR showed significant 
upregulation in the release of IL-6 [46, 47].
GM-CSF plays a pivotal role in the maturation, 
chemotaxis, survival and activation of eosinophils [34, 
48]. GM-CSF has also been involved in the regulation 
of glandular secretion by inducing lactoferrin release in 
nasal mucosa [49]. Furthermore, it has been reported 
that a significant correlation exists between GM-CSF 
concentrations in nasal secretions and in allergen-
specific immunoglobulin E antibodies to house dust 
mite Dermatophagoides pteronyssinus in patients with 
persistent AR [50].
On the other hand, it has been reported that CRS is 
associated with elevated levels of IL-8 in PBMCs, [51] 
sinus mucosa biopsies, [43, 45] and nasal secretions [44]. 
IL-8, in addition to its potent activity on neutrophils, 
can cause basophil histamine release and co-induce 
chemotactic activity for primed eosinophils [52, 53]. 
The activation and infiltration of eosinophils in AR and 
their release of proinflammatory mediators has also been 
described [54, 55]. Furthermore, high levels of IL-8 were 
detected in nasal secretions of patients with AR after the 
nasal provocation test [4], and upregulation in the release 
of IL-8 has been reported in primary cultures of human 
nasal epithelial cells from patients with AR [46].
Finally, it has been reported that the levels of sICAM-1 































1:102 + 10% HECM
Fig. 2 Time course of MP‑AzeFlu effects on HECM‑induced 
eosinophil survival. HECM at 10% from nasal mucosa (black circles) 
significantly increased eosinophil survival compared with control 
medium (white circles) from days 1 to 4. MP‑AzeFlu (grey circles) at 
dilution 1:102 significantly decreased eosinophil survival induced 
by HECM from days 2 to 4. Results are expressed as mean ± SEM 
percentage of eosinophil survival compared with HECM. ANOVA with 
the Dunnett multiple comparison test was used for analysis (N = 7). 
*P < 0.05; ***P < 0.001 compared with HECM. ANOVA analysis of 
variance, HECM human epithelial cell–conditioned media, MP‑AzeFlu 
intranasal azelastine hydrochloride and intranasal fluticasone 
propionate in a single device. SEM standard error of the mean
Table 3 Effect of  AZE, FP, and  MP-AzeFlu on  eosinophil 
survival induced by  human epithelial cell–conditioned 
media
Results are expressed as mean ± SEM. ANOVA with Dunnet multiple comparison 
test was used for analysis. *P < 0.05 compared with 10% HECM‑induced survival
ANOVA analysis of variance, AZE azelastine hydrochloride, HECM human 
epithelial cell‑conditioned media, FP fluticasone propionate, MP‑AzeFlu 
intranasal AZE and intranasal FP in a single device, SEM standard error of the 
mean
Dilution Eosinophil survival index, compared 
with HECM (%)
N
Day 3 Day 4
Control media 4.3 ± 0.8* 0.8 ± 0.5* 7
10% HECM 100 100 7
AZE
 1:102 75.2 ± 7.2* 44.0 ± 9.7* 7
 1:103 93.7 ± 3.5 78.8 ± 6.5 7
 1:104 93.1 ± 3.7 74.2 ± 8.2 7
 1:105 97.9 ± 1.4 76.1 ± 6.7 7
FP
 1:102 38.5 ± 3.5* 14.6 ± 4.0* 7
 1:103 54.4 ± 7.3* 18.9 ± 4.1* 7
 1:104 55.2 ± 8.3* 26.5 ± 5.6* 7
 1:105 57.1 ± 9.0* 29.1 ± 6.1* 7
MP‑AzeFlu
 1:102 17.5 ± 3.0* 2.4 ± 1.4* 7
 1:103 60.2 ± 5.5* 22.6 ± 5.1* 7
 1:104 57.6 ± 7.0* 21.6 ± 4.6* 7
 1:105 57.7 ± 6.4* 30.4 ± 7.6* 7
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with AR were significantly higher when compared with 
placebo [56, 57]. In addition, it has been shown that 
GM-CSF and ICAM-1 are important in determining the 
function of eosinophils, since in the presence of GM-CSF 
ICAM-1 has been shown to cause significant release of 
eosinophil-derived neurotoxin and EOS superoxide 
anion (O2-) generation [58].
Conclusion
In conclusion, we found that both MP-AzeFlu and 
FP reduce expression of important cytokines and 
reduce eosinophil survival. MP-AzeFlu lowers both 
nasal epithelial cell cytokine secretion and eosinophil 
survival more potently than antihistamine (AZE) or 
corticosteroid (FP) administered alone. This translational 
study demonstrates a mechanism of action that may 
underlie the superior clinical effect of MP-AzeFlu on AR 
and non-AR when compared with the component drugs 
used as monotherapy.
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Fig. 3 Comparison of AZE, FP, and MP‑AzeFlu effects on HECM‑induced eosinophil survival. Eosinophils were incubated for 3 and 4 days with 
culture medium (white column), 10% HECM (black), or 10% HECM plus AZE (diagonally striped), FP (horizontally striped), or MP‑AzeFlu (grey) at 
dilution 1:102. Results are expressed as mean ± SEM percentage of eosinophil survival compared with HECM. ANOVA with the Dunnett multiple 
comparison test was used for analysis (N = 7). *P < 0.05 compared with 10% HECM. ANOVA analysis of variance, AZE azelastine hydrochloride, HECM 
human epithelial cell–conditioned media, FP fluticasone propionate, MP‑AzeFlu intranasal AZE and intranasal FP in a single device. SEM standard 
error of the mean
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